CETP as a Target in HDL-raising Therapy:lessons from APOE*3-Leiden. CETP Transgenic Mice

Background Cardiovascular disease (CVD) is mainly caused by atherosclerosis,for which dyslipidemia (i.e. high (V)LDL-cholesterol (C),high triglycerides and low HDLC is a major risk factor. To reduce the risk to develop CVD,patients with dyslipidemia are usually treated with lipid-lowering drugs including statins and fibrates.

Background Cardiovascular disease （CVD） is mainly caused by atherosclerosis, for which dyslipidemia （ i. e. high （V） LDL-cholesterol （C）, high triglycerides and low HDLC is a major risk factor. To reduce the risk to develop CVD, patients with dyslipidemia are usually treated with lipid-lowering drugs including statins and fibrates. These drugs efficiently lower （V） LDLC （ up to - 40% ） and generally result in a modest increase in HDLC, but they only prevent a fraction of all cardiovascular events （ - 30% ）. Therefore new therapeutic strategies to reduce cardiovascular events more efficiently are necessary.